Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...

Mounjaro and Zepbound will continue to be crucial to Eli Lilly's progress. Here are two key things to watch. First, how quickly are their sales continuing to grow?

Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025.

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight ...

A new study reports that mice shed about 20% of their body weight and saw the size of their breast cancer tumors shrink after getting injected with tirzepatide, aka Mounjaro and Zepbound.